+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Membrane traffic in sphingolipid storage diseases



Membrane traffic in sphingolipid storage diseases



Traffic 1(11): 807-815



In this review, we summarize our studies of membrane lipid transport in sphingolipid storage disease (SLSD) fibroblasts. We recently showed that several fluorescent SL analogs were internalized from the plasma membrane predominantly to the Golgi complex of normal cells, while in ten different SLSD cell types, these lipids accumulated in endosomes and lysosomes (The Lancet 1999;354: 901-905). Additional studies showed that cholesterol homeostasis is perturbed in multiple SLSDs secondary to SL accumulation and that mistargeting of SL analogs was regulated by cholesterol (Nature Cell Biol 1999;1: 386-388). Based on these findings, we hypothesize that endogenous sphingolipids, which accumulate in SLSD cells due to primary defects in lipid catabolism, result in an altered intracellular distribution of cholesterol, and that this alteration in membrane composition then results in defective sorting and transport of SLs. The importance of SL/cholesterol interactions and potential mechanisms underlying the regulation of lipid transport and targeting are also discussed. These studies suggest a new paradigm for regulation of membrane lipid traffic along the endocytic pathway and could have important implications for future studies of protein trafficking as well as lipid transport. This work may also lead to important future clinical developments (e.g. screening tests for SLSD, new methodology for screening drugs which abrogate lipid storage, and possible therapeutic approaches to SLSD).

(PDF emailed within 1 workday: $29.90)

Accession: 046661764

Download citation: RISBibTeXText

PMID: 11208071


Related references

The genetics of sphingolipid hydrolases and sphingolipid storage diseases. Handbook of Experimental Pharmacology: 3-32, 2013

Sphingolipid biosynthesis and membrane traffic. Tanpakushitsu Kakusan Koso. Protein, Nucleic Acid, Enzyme 47(4 Suppl): 400-402, 2002

The biochemistry of sphingolipid storage diseases. Angewandte Chemie 16(5): 273-285, 1977

Storage diseases: New insights into sphingolipid functions. Trends in Cell Biology 13(4): 195-203, April, 2003

Broad screening test for sphingolipid-storage diseases. Lancet 354(9182): 901-905, 1999

Endocytic trafficking of glycosphingolipids in sphingolipid storage diseases. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 358(1433): 885-891, 2003

Antenatal diagnosis of sphingolipid and mucopolysaccharide storage diseases. Canadian Medical Association Journal 113(6): 507-511, 1975

Generation of lipid polarity in intestinal epithelial (Caco-2) cells: sphingolipid synthesis in the Golgi complex and sorting before vesicular traffic to the plasma membrane. Journal of Cell Biology 111(3): 977-986, 1990

Secondary alterations of sphingolipid metabolism in lysosomal storage diseases. Neurochemical Research 36(9): 1654-1668, 2012

A novel fluorescent ceramide analogue for studying membrane traffic in animal cells: accumulation at the Golgi apparatus results in altered spectral properties of the sphingolipid precursor. Journal of Cell Biology 113(6): 1267-1279, 1991

Innate immune responses in the brain of sphingolipid lysosomal storage diseases. Biological Chemistry 396(6-7): 659-667, 2016

How membrane dysfunction influences neuronal survival pathways in sphingolipid storage disorders. Journal of Neuroscience Research 94(11): 1042-1048, 2016

The role of sphingolipids in neuronal development: Lessons from models of sphingolipid storage diseases. Neurochemical Research 27(7-8): 565-574, August, 2002